Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

@article{Anderson2004EffectsOC,
  title={Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.},
  author={Garnet L. Anderson and Marian C Limacher and Annlouise R. Assaf and Tamsen L. Bassford and Shirley A A Beresford and Henry R. Black and Denise E. Bonds and Robert L. Brunner and Robert G. Brzyski and Bette J. Caan and Rowan T. Chlebowski and David Curb and Margery L. S. Gass and Jennifer Hays and Gerardo Heiss and Susan L. Hendrix and Barbara V. Howard and Judith Hsia and Allan Hubbell and Rebecca D. Jackson and Karen C Johnson and Howard L. Judd and Jane Morley Kotchen and Lewis H. Kuller and Andrea Z. LaCroix and Dorothy S Lane and Robert D. Langer and Norman Lasser and Cora E. Lewis and JoAnn E. Manson and Karen L. Margolis and Judith K. Ockene and Mary J. O’Sullivan and Lawrence S. Phillips and Ross L Prentice and Cheryl Ritenbaugh and John A Robbins and Jacques E Rossouw and Gloria E. Sarto and Marcia L Stefanick and Linda V Van Horn and Jean Wactawski‐Wende and Robert B. Wallace and Sylvia Wassertheil-Smoller},
  journal={JAMA},
  year={2004},
  volume={291 14},
  pages={
          1701-12
        }
}
CONTEXT Despite decades of use and considerable research, the role of estrogen alone in preventing chronic diseases in postmenopausal women remains uncertain. OBJECTIVE To assess the effects on major disease incidence rates of the most commonly used postmenopausal hormone therapy in the United States. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind, placebo-controlled disease prevention trial (the estrogen-alone component of the Women's Health Initiative [WHI]) conducted in 40… 

Figures and Tables from this paper

Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative
TLDR
CEE increases the risk of ischemic stroke in generally healthy postmenopausal women and in women with prior or current use of statins or aspirin and there was no convincing evidence to suggest that CEE had an effect on therisk of hemorrhagic stroke.
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
TLDR
Among postmenopausal women with prior hysterectomy followed up for 10.7 years, CEE use for a median of 5.9 years was not associated with an increased or decreased risk of CHD, deep vein thrombosis, stroke, hip fracture, colorectal cancer, or total mortality.
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.
TLDR
Conjugated equine estrogens provided no overall protection against myocardial infarction or coronary death in generally healthy postmenopausal women during a 7-year period of use.
The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.
TLDR
Subgroup analyses suggest that timing of hormone therapy (HT) initiation influences the relation between HT and coronary risk, as well as its overall benefit-risk balance, and systemic HT has an acceptable safety profile for menopause management when initiated among healthy women who are younger or recently menopausal and not at elevated risk for cardiovascular disease or breast cancer.
Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial
TLDR
In contrast to the preponderance of observational studies, conjugated equine estrogens in a randomized clinical trial did not reduce colorectal cancer incidence nor improve survival after diagnosis.
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
TLDR
For women who begin use soon after menopause, combined analyses of clinical trial and observational study data do not provide clear evidence of either an overall reduction or an increase in breast cancer risk with CEEs, although hazard ratios appeared to be relatively higher among women having certain breast cancerrisk factors or a low body mass index.
Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
TLDR
Unlike use of estrogen plus progestin, which increased deaths from lung cancer, use of conjugated equine estrogen alone did not increase incidence or death from Lung cancer.
Postmenopausal hormone treatment.
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
TLDR
Treatment with CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with prior hysterectomy, however, treatmentWith CEE increases the frequency of mammography screening requiring short interval follow-up, and initiation of CEE should be based on consideration of the individual woman's potential risks and benefits.
Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy.
TLDR
CEE does not appear to have enduring effects on rates of domain-specific cognitive change in older postmenopausal women, and was associated with lower spatial rotational performance after an average of 3 yr of treatment.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
TLDR
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
TLDR
Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.
TLDR
In postmenopausal women with coronary disease, neither HRT nor antioxidant vitamin supplements provide cardiovascular benefit and a potential for harm was suggested with each treatment.
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
TLDR
It is demonstrated that estrogen plus progestin increases BMD and reduces the risk of fracture in healthy postmenopausal women and there was no net benefit when considering the effects of hormone therapy on other important disease outcomes in a global model.
Estrogen plus progestin and the risk of coronary heart disease.
TLDR
Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.
A clinical trial of estrogen-replacement therapy after ischemic stroke.
TLDR
Estradiol does not reduce mortality or the recurrence of stroke in postmenopausal women with cerebrovascular disease and this therapy should not be prescribed for the secondary prevention of cerebroVascular disease.
Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS)
...
1
2
3
4
5
...